Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Alpha Cognition Inc. (TSX-V:ACOG, OTCQB:ACOGF), a biopharmaceutical company focused on neurodegenerative disorders, will present at the Planet MicroCap Showcase: VEGAS 2023 on April 26, 2023, at 10:30 AM PST. CEO Michael McFadden will lead the presentation and answer questions afterward. Interested investors can attend live via webcast or schedule one-on-one meetings at the conference in Las Vegas. Alpha Cognition is developing ALPHA-1062, a new treatment aimed at Alzheimer's disease, designed to minimize gastrointestinal side effects. Further details can be found on the Planet MicroCap website.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) has completed a second tranche of its private placement, issuing 6,952,427 units at $0.255 per unit, yielding gross proceeds of $1,772,869. This follows a first tranche, bringing total proceeds to $6,055,650 from 23,747,648 units. The funds will support clinical development programs, including a New Drug Application for ALPHA-1062, a new treatment for Alzheimer's disease. Securities are subject to a four-month hold period in Canada and a 12-month resale restriction in the U.S.
Alpha Cognition Inc. (TSX-V: ACOG, OTCQB: ACOGF) reported its financial results for Q4 and the full year ending December 31, 2022. The company is focused on submitting a New Drug Application (NDA) for ALPHA-1062, aimed at treating mild to moderate Alzheimer's disease, targeting a filing date in June/July 2023. Notably, R&D expenses increased to $8.8 million for 2022, driven by advancements in clinical studies. The company reported a net loss of $12.1 million for the year, with cash reserves of $2.1 million as of December 31, 2022. There is an ongoing effort to manage finances prudently and explore partnerships.